The aim of the present study was to observe the influence of the small breast epithelial mucin (MUCL1) (also known as SBEM) gene on migration and invasion ability of breast cancer cells and to explore the potentially involved mechanism. SBEM-interference plasmid and SBEM-overexpressing plasmid were constructed. SBEM-knockdown or SBEM-overexpressing MCF-7 and MDA-MB-231 breast cancer cells were established by lentivirus-mediated stable transfection method. The scratch wound-healing assay and Transwell chamber experiment were used to detect the influence of the SBEM gene on the migration and invasion abilities of MCF-7 and MDA-MB-231 cells. Real-time PCR (polymerase chain reaction) and western blotting were used to detect the expression of epithelial-to-mesenchymal transition (EMT)-related markers and regulators. The cell morphology was observed after transfection. The SBEM-knockdown or SBEM-overexpressing MCF-7 and MDA-MB-231 cells were established successfully. The migration and invasion abilities were decreased after SBEM was downregulated, and were increased after SBEM was overexpressed both in MCF-7 and MDA-MB-231 cell lines. The mRNA and protein expressions of N-cadherin, Twist and vimentin were elevated following SBEM overexpression, while the expression of E-cadherin and claudin-1 were found to be decreased following SBEM overexpression.In conclusion, SBEM has the potential to promote migration and invasion ability of breast cancer cells via promoting epithelial-to-mesenchymal transition.
ObjectiveThe aim of the study was to evaluate the efficacy and safety of etoposide plus thalidomide as maintenance therapy for elderly patients with advanced non-small cell lung cancer (NSCLC) without disease progression after first-line chemotherapy.MethodsAfter four to six cycles of platinum-based first-line therapy, 64 elderly patients with advanced NSCLC without disease progression who were treated in the General Hospital of Shenyang Military Region (China) from 2014 to 2016 were enrolled in this study. According to the different maintenance treatment methods, patients were divided as having received etoposide plus thalidomide therapy (treatment group, n= 32) and best supportive care (control group, n = 32). Disease control and progression-free survival (PFS) were compared between the two groups.ResultsThe recent curative effect objective response rates of the treatment group and the control group were 31.3% and 3.1%, respectively, and the disease control rates were 71.9% and 31.3%, respectively. The Kaplan-Meier survival curves of the two groups were significantly different (χ2 = 26.532, P = 0.001). The median PFS for the treatment group and control group was 6.0 months [95% confidence interval (CI) =4.3-7.9 months] and 3.2 months (95% CI = 2.6-3.8 months), respectively. The side effects in the treatment group included hematologic abnormalities, gastrointestinal toxicity, and impaired liver function, which were relieved after symptomatic support therapy and drug withdrawal.ConclusionEtoposide plus thalidomide as maintenance therapy is associated with a significantly longer PFS with tolerable toxicity for elderly patients with advanced NSCLC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.